Crossing barriers : the burden of inflammatory bowel disease across Western Europe
Kumar, Aditi (Queen Elizabeth Hospital (Birmingham, Regne Unit))
Yassin, Nuha (University Hospitals Birmingham)
Marley, Alexandra (The Royal Wolverhampton NHS Trust)
Bellato, Vittoria (University of Rome 'Tor Vergata')
Foppa, Caterina (Humanitas Research Hospital (Itàlia))
Pellino, Gianluca (Universitat Autònoma de Barcelona. Departament de Cirurgia)
Myrelid, Pär (Linköping University Hospital)
Millan, Monica (Hospital Universitari i Politècnic La Fe (València))
Gros, Beatriz (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Avellaneda, Nicolas (CEMIC University Hospital)
Catalan-Serra, Ignacio (Norwegian University of Science and Technology)
El-Hussuna, Alaa (Open Source Research Organisation, Aalborg)
Cunha Neves, João A. (Algarve University Hospital Centre)
Roseira, Joana (Algarve University Hospital Centre)
Cunha, Miguel F. (University of Algarve)
Verstockt, Bram (UZ Leuven)
Bettenworth, Dominik (University of Münster)
Mege, Diane (Timone University Hospital)
Brookes, Matthew J. (University of Wolverhampton)

Data:	2023
Resum:	An estimated 2. 5-3 million individuals (0. 4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant cost to the healthcare system of an estimated 4. 6-5. 6 billion euros per year. Hospitalisation and surgical resection rates are generally on a downward trend, which is contrary to the rising cost of novel medication. This signifies a large part of healthcare cost and burden. Despite publicly funded healthcare systems in most European countries, there is still wide variation in how patients receive and/or pay for biologic medication. This review will provide an overview and discuss the different healthcare systems within Western Europe and the barriers that affect overall management of a changing IBD landscape, including differences to hospitalisation and surgical rates, access to medication and clinical trial participation and recruitment. This review will also discuss the importance of standardising IBD management to attain high-quality care for all patients with IBD.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Matèria:	Crohn's disease ; Disease burden ; Healthcare ; Inflammatory bowel disease ; Trials ; Ulcerative colitis
Publicat a:	Therapeutic Advances in Gastroenterology, Vol. 16 (December 2023) , ISSN 1756-2848

DOI: 10.1177/17562848231218615
PMID: 38144422

16 p, 661.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats
Articles > Ressenyes